Rapid HIV Testing and Its Role in Advancing

  • Slides: 47
Download presentation
Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M.

Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M. D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and Prevention

Three FDA-approved Rapid HIV Tests Ora. Quick Reveal Uni-Gold Recombigen Sensitivity Specificity (95% C.

Three FDA-approved Rapid HIV Tests Ora. Quick Reveal Uni-Gold Recombigen Sensitivity Specificity (95% C. I. ) 99. 6 100% (98. 5 – 99. 9) (99. 7 – 100) 99. 8 99. 1 (99. 2 – 100) (98. 8 – 99. 4) 100 99. 7 (99. 5 – 100) (99. 0 – 100)

Three FDA-approved Rapid HIV Tests Specimen type CLIA category Fingerstick, whole blood, (oral fluid?

Three FDA-approved Rapid HIV Tests Specimen type CLIA category Fingerstick, whole blood, (oral fluid? ) Waived Reveal Serum, plasma Moderate Complexity Uni-Gold Recombigen Serum, plasma, whole blood Moderate Complexity Ora. Quick

Ora. Quick: Fingerstick, whole blood

Ora. Quick: Fingerstick, whole blood

Obtain finger stick specimen…

Obtain finger stick specimen…

… or whole blood

… or whole blood

Loop collects 5 microliters of whole blood

Loop collects 5 microliters of whole blood

Insert loop into vial and stir

Insert loop into vial and stir

Insert device; test develops in 20 minutes

Insert device; test develops in 20 minutes

Reactive Control Positive HIV-1 C C T T Positive Negative Read results in 20

Reactive Control Positive HIV-1 C C T T Positive Negative Read results in 20 – 40 minutes

Requirements for Ora. Quick Testing n Sold only to “clinical laboratories” n To perform

Requirements for Ora. Quick Testing n Sold only to “clinical laboratories” n To perform CLIA-waived tests, entities must: 1) Enroll in CLIA program 2) Obtain a Certificate of Waiver 3) Pay a biennial fee 4) Follow manufacturers’ instructions 5) Meet state requirements

Requirements for Ora. Quick Testing n Have an adequate quality assurance program n Assurance

Requirements for Ora. Quick Testing n Have an adequate quality assurance program n Assurance that operators will receive and use instructional materials n QA guidelines for Ora. Quick testing and sample forms: www. cdc. gov/hiv/rapid_testing

Oral fluid specimens: Reduce hazards, facilitate testing in field settings

Oral fluid specimens: Reduce hazards, facilitate testing in field settings

Reveal HIV-1 Rapid Antibody Test: Serum, Plasma

Reveal HIV-1 Rapid Antibody Test: Serum, Plasma

Centrifuge to obtain serum or plasma

Centrifuge to obtain serum or plasma

Add 20 drops of buffer to reconstitute conjugate. (Refrigerate to store)

Add 20 drops of buffer to reconstitute conjugate. (Refrigerate to store)

Add 3 drops buffer to moisten membrane

Add 3 drops buffer to moisten membrane

Add one drop of serum or plasma, followed by 3 drops of buffer.

Add one drop of serum or plasma, followed by 3 drops of buffer.

Add 4 drops of conjugate solution

Add 4 drops of conjugate solution

Add 3 drops of buffer to wash

Add 3 drops of buffer to wash

Positive Negative Read results immediately

Positive Negative Read results immediately

Uni-Gold Recombigen: Serum, plasma, whole blood

Uni-Gold Recombigen: Serum, plasma, whole blood

Add 1 drop specimen to well

Add 1 drop specimen to well

Add 4 drops of wash solution

Add 4 drops of wash solution

Read results in 10 minutes

Read results in 10 minutes

Point-of-Care Testing n To expand testing in non-clinical settings: – Fingerstick or oral fluid

Point-of-Care Testing n To expand testing in non-clinical settings: – Fingerstick or oral fluid specimen – One-step – Easy to interpret – Internal control

The Need for Training n n n Blood & body fluid precautions Obtaining the

The Need for Training n n n Blood & body fluid precautions Obtaining the specimen (finger stick or blood draw) Performing the test Providing test results and counseling Quality assurance OSHA requirements

Remember the tradeoffs… n Good News: More HIV-positive people receive their test results. n

Remember the tradeoffs… n Good News: More HIV-positive people receive their test results. n Bad News: Some people will receive a falsepositive result before confirmatory testing.

Reports from the 2003 HIV Prevention Conference n Promising news with rapid HIV tests

Reports from the 2003 HIV Prevention Conference n Promising news with rapid HIV tests for – – Routine screening in medical settings – Increasing receipt of results at CT sites – Screening in labor and delivery – Outreach testing

Routine HIV Screening in Medical Care Settings n Cook County Hospital ED, Chicago n

Routine HIV Screening in Medical Care Settings n Cook County Hospital ED, Chicago n Ora. Quick testing since October 02 o 60% accept HIV testing o 98% receive test results o 2. 8% new HIV positive o 80% entered HIV care n Now underway in Chicago, Boston, Los Angeles n 4 new demonstration projects (Wisconsin, Massachusetts, Los Angeles, New York)

HIV Screening in Acute Care Settings n n n Cook County ED, Chicago Grady

HIV Screening in Acute Care Settings n n n Cook County ED, Chicago Grady ED, Atlanta Johns Hopkins ED, Baltimore HIV testing sites 1. 3% New HIV+ 2. 3% 2. 7% 3. 2%

HIV Screening with Ora. Quick in Labor and Delivery: the MIRIAD Study n Testing

HIV Screening with Ora. Quick in Labor and Delivery: the MIRIAD Study n Testing of pregnant women in labor for whom no HIV test results are available; 12 hospitals in 5 cities: Atlanta, Chicago, Miami, New Orleans, New York n To date o 4597 women screened o 34 new HIV infections identified o 2 false positive Ora. Quick tests, no false negatives o 8 false-positive EIAs

Turnaround Times for Rapid Test Results, Point-of-Care vs Lab Testing n Point-of-care testing: median

Turnaround Times for Rapid Test Results, Point-of-Care vs Lab Testing n Point-of-care testing: median 45 min – (range 30 min – 2. 5 hours) n Same test in Laboratory: median 3. 5 hours – (range 94 min – 16 hours) MMWR 52: 36, Sept 16, 2003

Ora. Quick Outreach to High-risk Persons of Color n n n On-site testing at

Ora. Quick Outreach to High-risk Persons of Color n n n On-site testing at sites throughout the community Group pretest counseling. Individual testing and post-test counseling. Patrick Keenan MD University of Minnesota Medical School Department of Family Practice and Community Health

Ora. Quick Fingerstick Results: 7/02 – 6/03 N = 1021 n n n Preliminary

Ora. Quick Fingerstick Results: 7/02 – 6/03 N = 1021 n n n Preliminary positive True positives False Positives Sensitivity Specificity Positive Predictive Value 5 (0. 5%) 4 (0. 4%) 1 (0. 1%) 4/4 (100%) 1016/1017 (99. 9%) 4/5 (80%)

Results n 99. 7% of clients received their test results and post-test counseling. n

Results n 99. 7% of clients received their test results and post-test counseling. n The average time between fingerstick and learning test result was 28 minutes.

Client Survey Results n “I would rather have my finger stuck than have blood

Client Survey Results n “I would rather have my finger stuck than have blood drawn from my vein” Agree or strongly agree = 95% Disagree or strongly disagree = 5%

Post-Marketing Surveillance n 14 states in 2003, expansion in 2004 as more project areas

Post-Marketing Surveillance n 14 states in 2003, expansion in 2004 as more project areas implement rapid testing n (Note: Supplement to Program Announcement) n Monitoring: Ø Changes in utilization of testing Ø Acceptance (choice of tests) Ø Client and counselor satisfaction Ø Follow-up on false-positives Ø Adverse events

Initial Observations n 95% of persons opt for the rapid HIV test; 34% of

Initial Observations n 95% of persons opt for the rapid HIV test; 34% of those tested say they would not have been tested if rapid test not available (New York) n In one clinic for homeless persons, HIV prevalence among those tested rose from 4% to 12% after introduction of rapid tests (San Francisco) n 30% of the number of HIV-positive persons identified in all of last year were identified in the first month rapid testing was introduced (Utah) n 98% - 100% of those tested receive their test results

Post-Marketing Surveillance n In New York State test sites: 30% increase in persons tested

Post-Marketing Surveillance n In New York State test sites: 30% increase in persons tested Ø 85% increase in MSM Ø 42% increase in IDU Ø 96% increase in persons with hx of STD diagnosis n Counselors’ Ø Ø confidence in their overall role in rapid testing rose from 54% to 100% after first 12 weeks of testing scores on proficiency specimens at 12 weeks were 100%

Confirmatory Testing n For Western blot: o Venipuncture for whole blood o Oral fluid

Confirmatory Testing n For Western blot: o Venipuncture for whole blood o Oral fluid specimen o Dried blood spots on filter paper n Confirmatory test essential (not just EIA!)

Additional Resources General and technical information (updated frequently): www. cdc. gov/hiv/rapid_testing

Additional Resources General and technical information (updated frequently): www. cdc. gov/hiv/rapid_testing

Interpreting Rapid Test Results For a laboratory test: Sensitivity: Probability test=positive if patient=positive Specificity:

Interpreting Rapid Test Results For a laboratory test: Sensitivity: Probability test=positive if patient=positive Specificity: Probability test=negative if patient=negative Predictive value: Probability patient=positive if test=positive Probability patient=negative if test=negative

Example: Test 1, 000 persons Test Specificity = 99. 6% (4/1000) HIV prevalence =

Example: Test 1, 000 persons Test Specificity = 99. 6% (4/1000) HIV prevalence = 10% True positive: 100 False positive: 4 Positive predictive value: 100/104 = 96%

Example: Test 1, 000 persons Test Specificity = 99. 6% (4/1000) HIV prevalence =

Example: Test 1, 000 persons Test Specificity = 99. 6% (4/1000) HIV prevalence = 10% True positive: 100 False positive: 4 Positive predictive value: 100/104 = 96% HIV prevalence = 0. 4% True positive: 4 Positive predictive value: False positive: 4/8 = 50% 4

Positive Predictive Value of a Single Test Depends on Specificity & Varies with Prevalence

Positive Predictive Value of a Single Test Depends on Specificity & Varies with Prevalence Predictive Value, Positive Test HIV Prevalence Ora. Quic k 10% 99% 5% 98% 2% 95% 1% 91% 0. 5% 83% 0. 3% 75% 0. 1% 50% EIA 98% 96% 91% 83% 71% 60% 33% 92% 85% 69% 53% 36% 25% 10% Test Specificity 99. 9% 99. 8% 99. 1% Reveal